No Early Relief for JW Therapeutics from Cancer Wonder Drug
The biotech company logs revenue of 66 million yuan from its cutting-edge cancer therapy, but losses jump more than 50% to nearly 430 million yuan. Key Takeaways: JW Therapeutics prices…
Recent Articles
RELATED ARTICLES
-
Kintor shares plunge after hair-loss drug flops in clinical trials
9939.HK -
Akeso marks profit milestone with swift rights issue
9926.HK
-
RemeGen hopes for pain relief from expanded drug uses
9995.HK 688331.SHG
-
GenScript losses shrink on strong growth for cancer cell therapy
1548.HK
-
BeiGene still bleeding red ink despite blockbuster drug
BGNE.US 6160.HK 688235.SHG
